The QualityStocks Daily Thursday, November 21st, 2019

Today's Top 3 Investment Newsletters

QualityStocks (AXIM) +61.11%

InvestorPlace (SSI) +52.02%

StockMarketWatch (HEPA) +38.37%

The QualityStocks Daily Stock List

American BriVision (Holding) Corporation (ABVC)

TipRanks, Stockopedia, Real Investment Advice, Market Screener, Morningstar, GlobeNewswire, Stockwatch, Simply Wall St, Nasdaq, Street Insider, TMXmoney, Wallet Investor, 4-Traders, Stockhouse, and TradingView reported beforehand on American BriVision (Holding) Corporation (ABVC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

American BriVision (Holding) Corporation is a clinical stage biopharmaceutical company based in Fremont, California. It is developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology. The Company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. Established in 2015, American BriVision lists on the OTC Markets Group’s OTCQB.

American BriVision is concentrating on using its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions. These include Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. The Company then focuses on out-licensing the products to global pharmaceutical companies for pivotal Phase III studies and, eventually, generating international sales.

American BriVision released positive clinical results in June 2019 showing efficacy and safety for its ABV-1504 Phase II (Part 2) trial, under the U.S. Food and Drug Administration (FDA) and Taiwan FDA clinical protocol code of BLI-1005-002, in major depressive disorder (MDD). This study was a randomized, double-blind, placebo-controlled, multi-center trial. Sixty adult patients with confirmed moderate-to-severe MDD were treated with PDC-1421 low dose (380 mg), PDC-1421 high dose (2 x 380 mg), or placebo for 6 weeks, three times per day. PDC-1421 is the active pharmaceutical ingredient of ABV-1504.

PDC-1421 high dose (2 x 380 mg) met the prespecified primary endpoint by demonstrating a highly significant 13.2-point reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score by Intention-To-Treat (ITT) analysis, averaged over the 6-week treatment period from baseline ( overall treatment effect), versus a 9.2-point reduction in the placebo group. The results support further development of PDC-1421 in MDD. The low and high doses of PDC-1421 were safe and well tolerated with no serious adverse events.

In October, American BriVision announced encouraging results from the First-in-Human Clinical Trial (feasibility study or study) for Vitargus®, its investigational medical device. The results were first reported by Dr. Andrew Chang, the principal investigator of the feasibility study, on October 11, 2019, at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting.

Study results suggest Vitargus® is safe and well-tolerated and may be a viable vitreous substitute to be used in vitrectomy surgeries. Assuming sufficient funding, American BriVision will initiate a multi-national, multi-site pivotal study for Vitargus® next year.

Last week, American BriVision issued a full clinical study report (CSR), under the U.S. Food and Drug Administration (FDA) and Taiwan FDA (TFDA) clinical protocol code of BLI-1005-002, for ABV-1504 major depressive disorder (MDD) Phase II study. PDC-1421 high-dose data met the primary endpoint on MADRS scale in ITT clinical trial population.

PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no serious adverse events associated with them in the Phase II clinical trial. American BriVision is planning for end-of-Phase II meetings with regulatory authorities to discuss the way forward for Phase III pivotal trials.

American BriVision (Holding) Corporation (ABVC), closed Thursday's trading session at $6.80, even for the day, on 1,865 volume with 6 trades. The average volume for the last 3 months is 2,135 and the stock's 52-week low/high is $2.00/$37.7999992.

chart

AMMO, Inc. (POWW)

Infront Analytics, Dividend Investor, Stockhouse, 4-Traders, InvestorsHub, Simply Wall St, Seeking Alpha, GlobeNewswire, GuruFocus, Morningstar, Wallet Investor, YCharts, Barchart, The Street, Stockopedia, Stockwatch, Stockawiki, Investors Hangout, Business Insider, Market Screener, Trading View, and MarketWatch reported earlier on AMMO, Inc. (POWW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AMMO, Inc. is a technology leader and premier American ammunitions manufacturer. The Company designs and manufactures products for a variety of aptitudes. This includes law enforcement, military, hunting, sport shooting and self-defence. Established in 2016, AMMO is based in Scottsdale, Arizona. AMMO operates a munitions manufacturing facility in Payson, Arizona, and a brass casings manufacturing facility in Manitowoc, Wisconsin.

AMMO promotes branded munitions. These include its patented STREAK™ Visual Ammunition, the Jesse James line of munitions and accessories, /stelTH/ subsonic munitions, O.W.L. Technologies®, TAC-PTM Tactical Precision Defense munitions, and OPS (One Precise Shot). OPS is a lead-free frangible tactical line of munitions for self-defence.

The ammunition AMMO builds performs like high end custom hand loaded ammunition. The Company works to be the leading innovator of center-fire ammunition for military, law enforcement, and civilians. Every load is developed for a specific purpose.

The focus is on consistency, accuracy, and, in some cases, felt recoil. Each round is designed, manufactured, inspected and packaged to bring a first-rate shooting experience to AMMO’s end consumer. In addition, the Company’s HyperClean technology enables its customers to shoot more and clean less.

Last week, AMMO announced its sponsorship of the American Suppressor Association (ASA). The ASA is the unified voice of the suppressor community centered on nationwide pro-suppressor reform. Moreover, AMMO launched its improved line of /stelTH/™ ammunition designed purposely for use in suppressed firearms. The /stelTH/™ line is subsonic to lessen the sound signature to safe hearing levels when used with a suppressor. It is loaded using Hyperclean™ Technology to allow for a cleaner and more enjoyable shooting experience.

This week, AMMO announced the operational launch of its patented Hard Armor Piercing Incendiary (HAPI) and Armor Piercing (AP) ammunition manufacturing line. The Company is now manufacturing best-in-class 308 (7.62x51mm) and .338 ammunition in HAPI and AP variants for use by AMMO’s U.S. and overseas military and law enforcement partners. AMMO’s work in industrializing the manufacturing of its AP and HAPI ammunition was specifically deployed to serve the growing worldwide military and law enforcement ammunition market.

AMMO, Inc. (POWW), closed Thursday's trading session at $1.25, off by 0.793651%, on 10,047 volume with 20 trades. The average volume for the last 3 months is 10,916 and the stock's 52-week low/high is $1.00/$4.26000022.

chart

Cannabis Sativa, Inc. (CBDS)

The Hot Penny Stocks, Cannabis Stock Trades, Awesome Penny Stocks, CannabisMarketCap, OTC Markets, Micro Small Cap, Micro Cap Daily, Stockwatch, Investing Daily, Green Rush Review, Stockopedia, TipRanks, Daily Marijuana Observer, Stockhouse, NIC Investors, and Dividend Investor reported earlier on Cannabis Sativa, Inc. (CBDS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cannabis Sativa, Inc. engages in the licensing of cannabis related intellectual property (IP), marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. Additionally, the OTCQB-listed Company seeks strategic partners for the acquisition of operating companies, IP and other assets that fit within its corporate vision. Cannabis Sativa’s goal is to brand and market the highest quality, legal cannabis and hemp products and to innovate. Cannabis Sativa is headquartered in Mesquite, Nevada.

The Company licenses the "hi" and "White Rabbit" brands, and also holds a United States patent on the Ecuadorian Sativa strain of Cannabis, and a United States Patent for a marijuana lozenge. In addition, the Company holds a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery and trade secret formulas and processes.

Cannabis Sativa also offers the hi benefits discount pharmacy card, and operates different subsidiaries. These subsidiaries include PrestoDoctor(R), Wild Earth Naturals(R), and iBudtender. Furthermore, the Company is the official licensee for the Virgin Mary Jane Brand.

Cannabis Sativa foresees a future where the hi Brand is synonymous with the highest quality and best value in the space. hi Brands International concentrates on premium CBD (cannabidiol) & THC (tetrahydrocannabinol) products. Only pure sourced, all-natural ingredients go into Cannabis Sativa’s Hemp, CBD, and THC infused products.

This week, Cannabis Sativa announced that its focus on operational improvement continues to pay off across the board in all of its key financial metrics. For the nine-month period ended September 30, 2019, Revenue increased 72 percent, to $705k, from a year ago. Gross Margin improved 71 percent from the comparable 2018 period ($413k vs. $241k), at 59 percent of Revenue.

PrestoDoctor's patient growth and geographic expansion were the chief drivers for the improved Revenue and Margins. Operating Loss for the nine months ended September 30, 2019, was $1.7 million. This represents an improvement of $1.4 million (42 percent) from the same period in the previous year.

Cannabis Sativa, Inc. (CBDS), closed Thursday's trading session at $0.6198, up 17.1312%, on 623,976 volume with 413 trades. The average volume for the last 3 months is 60,544 and the stock's 52-week low/high is $0.50/$4.50.

chart

Gran Colombia Gold Corp. (TPRFF)

Micro Small Cap, Market Screener, Resource World, Junior Mining Network, Metals News, Mining & Energy, Stockhouse, Gold Stock Data, Wallet Investor, Stockwatch, The Prospector News and TradingView reported earlier on Gran Colombia Gold Corp. (TPRFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Gran Colombia Gold Corp. is a mid-tier gold producer. The Company’s chief focus is in Colombia where it is now the largest underground gold and silver producer with several mines in operation at its Segovia and Marmato Operations. Gran Colombia is now in the midst of an expansion and modernization project at its high grade, production stage Segovia Operations. Gran Colombia Gold is based in Toronto, Ontario.

The Company’s emphasis is on the development of the Segovia Operations and Marmato projects to produce strong cash flows in the short, medium, and also long term. Gran Colombia produces gold from the Segovia Operations, an area of around 9,000 hectares in the Segovia-Remedios mining district of Antioquia. The Segovia Operations include the El Silencio, Providencia, and Sandra K underground mines in the Municipality of Segovia, and the Carla underground mine in the Municipality of Remedios, situated roughly 10 km southeast of the Segovia mines.

The Marmato Project contains total estimated resources of approximately 8 million ounces of gold and close to 38 million ounces of silver positioned in the Caldas department in the core of the Middle Cauca gold district. The Marmato Project has first-rate infrastructure, being located by the Pan American Highway with access to Medellin to the north and Manizales to the south. It has access to the national electricity grid which runs near the property.

Additionally, Gran Colombia Gold has its Zancudo project. The Zancudo project is in the Titiribí mining district of Antioquia. It consists of an historical gold mine, the Independencia Mine, in the Middle Cauca Gold Belt, which produced about 130,000 ounces of gold with recovered grades of 14.6 g/t Au and 108.4 g/t Ag.

Earlier in November, Gran Colombia Gold announced multiple additional higher-grade gold intercepts over broad widths from 21 diamond drill holes (11,600 meters) drilled into the Marmato Deeps Zone (MDZ) as part of the continuing 2019 Phase 1 and Phase 2 infill drilling program at its Marmato Project in Caldas, Colombia. This includes 73.63 meters at 5.72 g/t Au in Drill Hole MT-IU-041.

Gran Colombia Gold remains on course to meet its gold production guidance for 2019. With 56,271 ounces produced in Q3 of 2019, versus 57,163 ounces in Q3 of 2018, total production for the first nine months of 2019 was 174,754 ounces. This is up 7 percent over the first nine months last year. With another 21,011 ounces produced in October, Gran Colombia’s trailing 12-months’ gold production at the end of October now stands at 232,960 ounces. This is up 7 percent over 2018’s annual production.

Gran Colombia Gold Corp. (TPRFF), closed Thursday's trading session at $3.47, off by 3.8781%, on 3,921 volume with 16 trades. The average volume for the last 3 months is 45,401 and the stock's 52-week low/high is $1.79999995/$4.4440999.

chart

NaturalShrimp Incorporated (SHMP)

Wall Street Analyzer, Micro Cap Daily, SeafoodSource, Micro Small Cap, Stockwatch, Emerging Growth, OTC Markets, Otc.watch, Transparent Traders, Market Screener, Live Trading News, Stockhouse, Insider Financial and Stockopedia reported beforehand on NaturalShrimp Incorporated (SHMP), and we also report on the Company, here at the QualityStocks Daily Newsletter.

NaturalShrimp Incorporated produces naturally-grown shrimp in the United States and worldwide. It is a leader in the “Closed-System Shrimp Farming” industry. In 2016-17, the Company introduced its patented vibrio suppression technology that is potentially disruptive to the entire shrimp farming industry.

An AquaCulture Company and OTCQB-listed, NaturalShrimp has its head office in Addison, Texas. It has production facilities located near San Antonio, Texas. NaturalShrimp’s European partner has built a production facility in Medina del Campo, Spain. Expansion plans include domestic and international production facilities and distribution channels.

NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp reliably and economically in an indoor, re-circulating, saltwater facility. Its eco-friendly, bio-secure design does not rely on ocean water. It recreates the natural ocean environment allowing for high-density production that can be replicated anywhere worldwide.

The water systems used in production are electrified systems that help to control ammonia and bacteria, killing 99 percent of all bacteria. Shrimp are brought into the facility at 28 days old and are raised until maturity. This happens around 14 weeks of age. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.

NaturalShrimp, employing its patented technology, continues to maintain the shrimp it stocked in July 2018, mainly to have fully grown shrimp for sampling to interested parties. The Company is now stocking shrimp on a monthly basis until required equipment is in place. It will then stock two lots of shrimp per month until its present facility is full, expected to be by the end of this year. NaturalShrimp will then begin harvesting.

Last month, NaturalShrimp and F&T Water Solutions, LLC, the aquaculture companies that developed and patented the first commercially-operational RAS (Recirculating Aquaculture System) for shrimp, announced the final testing of two additional next generation electrocoagulation (EC) systems for installation at its pilot plant in La Coste, Texas. NaturalShrimp witnessed successful final testing of the two new EC systems on October 17, 2019 at the IP Automation, Inc. facilities in Colorado Springs, Colorado. Furthermore, NaturalShrimp ordered three smaller EC systems to provide isolated filtration of the pilot plant nursery tanks.

Mr. Tom Untermeyer, Chief Technology Officer of NaturalShrimp, said, “These third generation EC units will work alongside the other first and second generation EC systems already in use on site at the pilot plant as part of the patented filtration system. Although the first and second generation EC units continue to perform well, and as expected, this third generation design includes some additional automation features as we continue to make improvements.”

NaturalShrimp Incorporated (SHMP), closed Thursday's trading session at $0.102, off by 2.8571%, on 1,978,212 volume with 143 trades. The average volume for the last 3 months is 2,689,450 and the stock's 52-week low/high is $0.008999999/$0.949.

chart

PharmaCielo Ltd. (PHCEF)

Small Cap Power, Stock Twits, Market Screener, InvestorsHub, Technical420, New Cannabis Ventures, Stocks News Feed, Investing.com, Stockhouse, PR Newswire, Trading View, Stock Target Advisor, Baystreet, National Institute for Cannabis Investors, Proactive Investors, and Dividend.com reported earlier on PharmaCielo Ltd. (PHCEF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

PharmaCielo Ltd. is the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. PharmaCielo is a global company with a focus on ethical and sustainable processing and supplying of all-natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. The Boards of Directors and Executive teams of PharmaCielo and PharmaCielo Colombia Holdings consist of a distinctly talented group of international business executives and specialists with relevant and diverse expertise. PharmaCielo is headquartered in Toronto, Ontario and lists on the OTC Markets.

PharmaCielo's main, and wholly-owned subsidiary, PharmaCielo Colombia Holdings S.A.S., is headquartered at its nursery and propagation center in Rionegro, Colombia. PharmaCielo is the first company to hold Colombian licences for cannabis with unrestricted percentages of tetrahydrocannabinol (THC) and cannabidiol (CBD). This makes it the world’s largest licensed producer (LP).

PharmaCielo’s facility features 12.1 hectares (1.3 million square feet) of open-air greenhouses ready for cultivation. It will supply plant seedlings to more than 1,000 hectares (2,500 acres) of contract growers’ open-air greenhouses for final cultivation. The Company is working on the construction and commercial commissioning of a downstream processing facility.

This past September, PharmaCielo announced it signed a United States sales agreement with an established multi-state distributor, General Extract LLC. According to the non-exclusive Agreement, PharmaCielo will provide the distributor with bulk medicinal CBD isolate meeting the purity requirements of the 2018 USA Farm Bill, for sale in numerous states including California and Colorado. The Agreement addresses the balance of 2019. In addition, it allows for renewal and volume expansion in 2020 based on market demand.

This Agreement marks PharmaCielo's first venture into the coveted U.S. market as a supplier of medicinal-grade CBD isolate. This allows it to expand its offerings in the near future with additional CBD products consistent with the 2018 Farm Bill.

PharmaCielo Ltd. (PHCEF), closed Thursday's trading session at $2.646, up 10.7113%, on 19,780 volume with 76 trades. The average volume for the last 3 months is 45,006 and the stock's 52-week low/high is $1.89999997/$9.97500038.

chart

Q BioMed, Inc. (QBIO)

NetworkNewsWire, Zacks, Market News Updates, TipRanks, Barchart, Market Screener, Wallet Investor, InvestorsHub, Stockhouse, Stockwatch, PR Newswire, Simply Wall St, Proactive Investors, MarketBeat, and Insider Financial reported previously on Q BioMed, Inc. (QBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Q BioMed, Inc. is a biotechnology acceleration company based in New York, New York. It acquires, develops and finances undervalued biomedical assets. The Company’s vision is to create a pipeline of unique biomedical assets in diverse stages of development in numerous therapeutic areas. Its Food and Drug Administration (FDA) approved, non-opioid drug is Metastron. Q BioMed’s shares trade on the OTC Markets’ OTCQB.

The Company’s Metastron relieves cancer bone pain. Metastron is approved for sale in 21 other countries. Further to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed’s plan is to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.

Q BioMed also has its Uttroside-B. Uttroside-B is up to 10 times more potent against liver cancer cells than Sorafenib (preclinical data), the only FDA approved drug for first line treatment of liver cancer. The Company plans to file an IND with the FDA this year to commence a clinical trial in this indication. In addition, Q BioMed has its QBM-001 for Pediatric Non-Verbal Disorder in dire need of treatment.

Furthermore, Q BioMed has its Man-01 to treat glaucoma. Man-01 has shown to normalize Intraocular Eye Pressure (IOP) that is present in glaucoma patients. Q BioMed expects to submit an IND to the FDA this year. The Mannin platform has a number of potential drugs for treating vascular disease.

Yesterday, Q BioMed announced FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture Q BioMed's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. Strontium-89 is an FDA-approved non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer. The product is administered intravenously once every three months as an alternative to opioid analgesics. It plays a vital role in the treatment of metastatic bone pain.

The approval of this facility means that this important oncologic pain drug will soon be available to patients in the United States and worldwide. Q BioMed is now the only FDA-approved source for this drug in the western world. The Company is activating its planned commercial operations to support marketing, sales, and distribution in the United States and, soon, globally.

Q BioMed, Inc. (QBIO), closed Thursday's trading session at $1.60, off by 1.2346%, on 1,501,009 volume with 2,026 trades. The average volume for the last 3 months is 145,521 and the stock's 52-week low/high is $0.34009999/$2.53999996.

chart

Zinc One Resources, Inc. (ZZZOF)

NetworkNewsWire, 4-Traders, MarketWatch, YCharts, InvestorX, InvestorsHub, Market Screener, Wall Street Profiler, Streetwise Reports, InvestorIntel, Stock of the Week, Epic Stock Picks, All Penny Stocks, Stockhouse, Dividend Investor, Insider Financial, Marketwired, Investing News, Barchart, StockInvest, Wallet Investor, Investor Ideas, and Investors Hangout reported previously on Zinc One Resources, Inc. (ZZZOF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Zinc One Resources, Inc. concentrates on the acquisition, exploration and development of prospective and advanced zinc projects in mining-friendly jurisdictions. Its key assets are the past producing Bongará Zinc Mine Project and the Charlotte-Bongará Zinc Project in Peru. The Company formerly went by the name Rockridge Capital Corp. It changed its corporate name to Zinc One Resources, Inc. in January 2017. Zinc One Resources is based in Vancouver, British Columbia.

The Company acquired Forrester Metals, Inc. in June of 2017. As a result, it acquired the Bongará Mine and Charlotte-Bongará Projects. Both host high-grade, nonsulphide zinc mineralization at or near the surface. At the Bongará Zinc Mine the mineralization is concentrated along and proximal to a NW – trending anticlinal axis over approximately 2.5 kilometers.

The Bongará Zinc Mine was mined in 2007 and 2008 by a previous owner by open-pit methods, dried at the site, and then shipped 540 kilometers westward to the coast where it was processed via a Waelz kiln. This is a processing technology usually applied to flue dust from steel mills to recover zinc. In August 2008, the mine was closed down mainly due to a drop in the price of zinc at that time.

The exploration upside at Charlotte-Bongará includes greater than 8,000 meters of drilling. This includes results of 29.5% Zn across 15.5 meters, 26.1% Zn across 12.5 meters, and 29.7% Zn across 11.5 meters.

Last month, Zinc One Resources announced the first National Instrument 43-101 (NI 43-101) Mineral Resource estimate for its Bongará Zinc Mine project in north-central Peru. Watts Griffis and McOuat Limited (WGM) prepared the estimate for the Company. A supporting NI 43-101 technical report will be available under Zinc One Resources’ profile on SEDAR at www.sedar.com and on the Company's website at www.zincone.com within 45 days of this release (dated February 5, 2019).

Yesterday, Zinc One Resources announced the results of voting at the Company’s Annual General Meeting (AGM) of shareholders that took place on March 13, 2019, in Vancouver, British Columbia. Shareholders at the AGM approved all matters. This included the appointment of the four incumbent directors - Dr. William C. Williams, Mr. Barry Girling, Mr. Greg Crowe, and Mr. Gunther Roehlig, for the following year, the re-appointment of Charlton & Co. LLP as auditors of Zinc One Resources, and the renewal of the Company's 10 percent rolling stock option plan.

Zinc One Resources, Inc. (ZZZOF), closed Thursday's trading session at $0.0113, up 41.25%, on 4,000 volume with 1 trade. The stock's 52-week low/high is $0.000099999/$0.081299997.

chart

Thunder Mountain Gold, Inc. (THMG)

Streetwise Reports, InvestorsHub, FeedBlitz, Zacks, Marketbeat, Silicon Investor, Simply Wall St, The Street, Wallet Investor, 24hgold, Morningstar, MarketWatch, Business Wire, Pink Investing, GuruFocus, and Junior Mining Network reported earlier on Thunder Mountain Gold, Inc. (THMG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Thunder Mountain Gold, Inc. is a junior gold exploration company listed on the OTCQB. It owns interests in manifold U.S. precious metals projects. The Company’s primary asset is The South Mountain Project. The South Mountain Project is on private and patented land in southern Idaho, just north of the Nevada border. Established in 1935, Thunder Mountain Gold has its corporate headquarters in Boise, Idaho.

The Company owns 100 percent of the South Mountain Mine. This mine has a land package consisting of roughly 1,200 acres of mostly private land - both owned outright and leased. In 2009, a new gold discovery was revealed during fieldwork at South Mountain.

Thunder Mountain Gold’s plan of operation for this, subject to business conditions, is to continue to advance the development at the South Mountain Project. The main metals at South Mountain are silver, zinc, lead, copper, and gold. The flagship South Mountain Project remains Thunder Mountain Gold’s focus. 

The Company also has its Trout Creek Project. The Trout Creek target is in the Reese River Valley area south of Battle Mountain, Lander County, Nevada. This is a grass roots gold target in the Eureka-Battle Mountain trend of central Nevada, now under Joint Exploration Agreement with Newmont USA Limited.  This target consists of 60 unpatented lode mining claims.

  Thunder Mountain Gold’s other projects include Clover Mountain. It controls 40 unpatented lode mining claims encompassing approximately 800 acres, near Clover Mountain in Owyhee County, Idaho. Additionally, the Company’s West Tonopah Property consists of 8 unpatented lode mining claims totaling 160 acres in the Tonopah Mining District, Esmeralda County, Nevada.

In 2018, Thunder Mountain Gold announced that it filed a new National Instrument 43-101 (NI 43-101) Technical Report, which included a new mineral resource estimate on the South Mountain Project. The Technical Report has an effective date of April 7, 2018.

Hard Rock Consulting, LLC (HRC) of Lakewood, Colorado completed the Technical Report for the South Mountain Project. HRC concluded that significant potential exists to increase the known mineral resource with additional drilling, and to upgrade existing mineral resource classifications with further infill drilling.

Earlier this month, Thunder Mountain Gold announced that in connection with the execution of the earlier announced BeMetals Option Agreement on the Company's South Mountain Project, shareholders of the Company holding approximately 53 percent of the issued and outstanding shares of Thunder Mountain Gold executed voting support agreements in favor of BeMetals Corp. and its wholly-owned subsidiary, BeMetals USA Corp. With the Voting Support Agreements, these shareholders have agreed to vote in favor and consent to the approval of the transactions set forth in the Agreement. BeMetals completed the Tranche 1 cash payment of US$100,000 to Thunder Mountain Gold by way of its wholly-owned subsidiary, Thunder Mountain Resources, Inc.

Thunder Mountain Gold, Inc. (THMG), closed Thursday's trading session at $0.1429, even for the day, on 1,201 volume. The average volume for the last 3 months is 4,595 and the stock's 52-week low/high is $0.030999999/$0.142900004.

chart

TechCare Corp. (TECR)

InvestorsHub, MarketWatch, Stockhouse, OTC Markets, Investing, 4-Traders, GuruFocus, Morningstar, YCharts, Penny Stock Tweets, PR Newswire, Investors Hangout, Seeking Alpha, Wallet Investor, Stockwatch, Barchart, last10k, Dividend Investor, Emerging Growth, and Market Screener reported earlier on TechCare Corp. (TECR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

TechCare Corp. has an inventive delivery platform that utilizes vapor technology for natural health and beauty treatments. The Company engages in the design, development, and commercialization of this unique delivery platform using vaporization of different natural, plant-based compounds, to enable a wide variety of treatment solutions. A technology company and OTCQB-listed, TechCare is based in New York City.

The Company has a strategic partnership agreement with HoMedics, one of the world's leading brands in health and wellness products. HoMedics manufactures, markets, and distributes TechCare's Novokid products in the United States, Canada, Brazil, Argentina, Colombia, and Costa Rica. These products are co-branded as HoMedics products powered by TechCare.

Novokid consists of a portable device that vaporizes TechCare's all-natural, plant-based solution contained in a disposable capsule. It comes with a proprietary head cap. Novokid is 100 percent natural, plant-based and pesticide-free. Novokid is the first of its type home use device. It presents a scientifically proven solution to eliminate lice, super lice, as well as eggs.

Novokid uses a proprietary vapor-based delivery platform. TechCare’s Novokid has received CE Mark approval as a CLASS I Medical Device. Novokid uses a simple 10-minute dry treatment. The treatment requires no rinsing or washing and is fast, dry, and clean. It is easily administered at home or while mobile. In addition, Novokid can be used as a maintenance and preventative treatment if used regularly.

The Company’s Shine is a hair treatment device. It underwent development with globally renowned industry leaders. Shine cleanses the hair and scalp. It also rejuvenates hair by returning its natural health, shine, body and luster. The expectation is that Shine will launch later in 2019.

TechCare announced in May of 2018 that following intensive research and development (R&D) and investments, it expanded its existing Intellectual Property (IP) portfolio with a previously submitted patent application of its Smart Capsule™ technology. Building upon its existing patents and knowledge, the new Smart Capsule™ technology enables the vaporization of two or more compounds simultaneously. As a result, this expands the range of applications while yielding superior performance, usability and ease-of-use.

Last month, TechCare announced that on January 21, 2019, it entered into a joint venture (JV) contract with China-Israel Biological Technology Co. Ltd. (CIB). With this agreement, TechCare's subsidiary Novomic Ltd. and CIB agreed to create a Chinese JV company in China.

The JV will concentrate on the field of health and cosmetics, including medical care, home care, hair care, and body and skin care, to develop a comprehensive and extensive range of health, wellness, beauty and home products for customers by using TechCare's patented technology of vaporization of natural and plant-based compounds. The JV’s intention is to sell its products in the Greater China region, including mainland China, Hong Kong, Macao and Taiwan, directly or through others.

TechCare Corp. (TECR), closed Thursday's trading session at $0.035, even for the day, on 32,099 volume with 9 trades. The average volume for the last 3 months is 3,981 and the stock's 52-week low/high is $0.0251/$0.384000003.

chart

FISION Corp. (FSSN)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, InvestorsHub, InvestorPoint, The Street, Wallet Investor, Market Screener, OTC Markets, Stockwatch, Dividend Investor, Investing, YCharts, Barchart, TradingView, MarketWatch, Business Wire, GuruFocus, and Capital Market Access reported earlier on FISION Corp. (FSSN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.  

FISION Corp. is a cloud-based digital asset management and marketing automation company. It serves  enterprise clients in the healthcare, hospitality, financial/insurance, software, and technology industries. The Company is an effective sales enablement and marketing asset management tool. Established in 2011 and OTCQB-listed, FISION is based in Minneapolis, Minnesota.

  FISION maximizes the brand potential of every sales interaction. The Company’s advanced, proprietary technology specializes in managing customers’ brand and marketing content. This enables marketing and sales people to quickly and easily create compelling, personalized, on-brand communications that increase revenue and profits.

FISION equips marketing and sales teams with a wide-ranging  set of enablement capabilities built to solve distributed marketing challenges. FISION’s solutions include simplified brand distribution, sales enablement, distributed & localized marketing, digital asset management, channel support, and measurement & analytics. FISION’s centralized, cloud-based library supports manifold different file types. It gives a client complete control over how company assets are stored, retrieved, and used.

FISION completed the acquisition of Volerro Corporation (Minneapolis, Minnesota-based) following the announcement of a definitive purchase agreement on April 25, 2017. Volerro is a leader in cloud-based content collaboration and agile marketing technology. Volerro enhances the FISION platform with complementary cloud-based collaboration, agile marketing, and sales enablement software.  Volerro’s ReVu.Me cloud app allows team members to work on the same document in real-time with integrated chat and voice conferencing.

In August 2018, FISION announced a merger agreement with Continuity Logic LLC. FISION's "front of the house" sales and marketing solution is complemented by Continuity Logic's "back of the house" enterprise integration & user-friendly application interface. This agreement in 2018 allowed both companies to immediately take advantage of each others customer base and sales pipeline, with no current overlapping of clients.

In October 2018, FISION announced it was named the #1 software company in Minnesota by Twin Cities Business (TBC) magazine. FISION is the category winner in the publication’s 2018 Best of Business Reader’s Choice Awards. FISION currently has greater than 65,000 users across 21 countries.

FISION Corp. (FSSN), closed Thursday's trading session at $0.015, up 45.6311%, on 237,700 volume with 14 trades. The average volume for the last 3 months is 69,684 and the stock's 52-week low/high is $0.009499999/$0.189999997.

chart

AXIM Biotechnologies, Inc. (AXIM)

TopPennyStockMovers, BioSpace, CFN Media Group, Simply Wall St, Promotion Stock Secrets, Insider Financial, Market Screener, Daily Marijuana Observer, Wallet Investor, and SmallCapVoice reported earlier on AXIM Biotechnologies, Inc. (AXIM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

AXIM Biotechnologies, Inc. is a biotechnology company listed on the OTC Markets Group’s OTCQB. It focuses on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. AXIM discovers and brings to market unique solutions through research and development (R&D), strategic partnerships, and acquisitions through setting the green standard in the industrial hemp industry. Medical Marijuana, Inc. (MJNA) is a major investor in AXIM.  AXIM Biotechnologies has its corporate headquarters in New York, New York.

AXIM’s emphasis is on inventive, proprietary delivery mechanisms for the introduction of cannabinoids and finding solutions for conditions for which there is currently no effective treatment. The Company is advancing its patented controlled-release cannabinoid gum in studies encompassing several indications.

At present, AXIM’s Intellectual Property (IP) portfolio includes two fully issued patents – one patent permitting the use of CBD (cannabidiol) in controlled-release, functional chewing gum, and another patent for chewing gum containing natural and synthetic cannabinoids for the treatment of pain,  and 15 patent applications in different stages of approval.

The Company’s flagship CanChew Plus® contains 10mg of cannabidiol (CBD) obtained from industrial hemp plants. AXIM also has its CanChew+ 50®. This product contains 50 mg of CBD. CanChew+ 50®is undergoing clinical trials in patients with IBS (Irritable Bowel Syndrome).

  Furthermore, the Company’s pipeline of IP protected cannabinoid-based products includes MedChew Rx™. This THC/CBD cannabinoid controlled-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients. It is the world’s first patented cannabinoid controlled-release chewing gum.

Last month, AXIM Biotechnologies announced that the United States Patent and Trademark Office (USPTO) issued a patent (US 10,172,786) on oral care compositions consisting of cannabinoids, including cannabidiol (CBD) and/or cannabigerol (CBG). The USPTO granted this patent from AXIM Biotechnologies’ patent application filed on December 15, 2015.

Products that the Company could produce under the patent will be made using cannabinoids. The patented formula maximizes the presence of CBD in the oral cavity during brushing. Also, all formulations via this patent will include CBD. AXIM hopes to use this patent in the development of products for the treatment of oral infectious disease. This includes peri implantitis, periodontitis, oral mucositis, and dental pain.

AXIM Biotechnologies, Inc. (AXIM), closed Thursday's trading session at $0.58, up 61.1111%, on 258,827 volume with 172 trades. The average volume for the last 3 months is 49,120 and the stock's 52-week low/high is $0.355500012/$2.50.

chart

Liberty Leaf Holdings Ltd. (LIBFF)

NetworkNewsWire, Penny Stock Hub, Stocks To Buy Now, TipRanks, Stockwatch, Investorx, Barchart, Capital Cube, Stockhouse, The Seed Investor, Cannabis News Wire, MarketWatch, InvestorsHub, and Investors Hangout reported on Liberty Leaf Holdings Ltd. (LIBFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Liberty Leaf Holdings Ltd.’s focus is to build and support a diverse portfolio of cannabis-sector businesses. This includes cultivation, cannabidiol (CBD)/tetrahydrocannabinol (THC) products, biotechnology research and supply-chain products within this fast-developing sector. Liberty Leaf Holdings is based in Vancouver, British Columbia.

The Company works to acquire partnership interests in up-and-coming and established companies in the medicinal and recreational cannabis arena. Liberty Leaf operates in Canada and is looking to enter the varied legal cannabis markets in North America.

Liberty Leaf Holdings announced in December of 2017 that it acquired a majority interest in Just Kush Enterprises. Just Kush owns complete control over a current Medical Marijuana Access Regulations (MMAR)-licensed production facility. This acquisition complements Liberty Leaf Holdings’ purchase in 2016 of North Road Ventures. North Road concentrates on the value-added aspect of the cannabis product processing business, sales, and complementary distribution. North Road Ventures is a developing distributor of cultivated and manufactured cannabis products to licensed legal retailers. North Road is expanding into the recreational market.

Mr. Will Rascan, Liberty Leaf Holdings’ President and Chief Executive Officer, announced in March 2018 the signing of an agreement between North Road Ventures, a wholly-owned subsidiary of Liberty Leaf, and Cannabis Compliance, Inc. (CCI). Under the agreement, CCI will be responsible for guiding the Good Manufacturing Practice (GMP)-compliant processing/production of North Road's cannabis-containing and other finished products.

Last month, PUF Ventures, Inc., an advanced Access to Cannabis for Medical Purposes Regulations (ACMPR) license applicant, and Liberty Leaf Holdings announced the execution of a Memorandum of Understanding (MOU) that outlines the basis where the Parties will undertake the creation of a joint venture (JV) partnership to develop a medical cannabis project for the cultivation and sale of medical cannabis in Greece. At present, the JV company is in talks with potential local partners with suitable resources and expertise to participate in the development of a large-scale, medical cannabis commercial cultivation operation.

This week, Liberty Leaf Holdings announced that work at Just Kush is now complete on the buildout of its "Phase I" cultivation production facility. Therefore, on October 29-30, 2018, Cannabis Compliance (CCI) will conduct its site visit walk through of the Just Kush facility and gather video footage as part of the Affirmation of Readiness (AOR) submission to Health Canada.

Mr. Will Rascan said, "I am very excited with the final result of the completed buildout. Coupled with our innovative technologies, what this means is that Just Kush can now officially notify Health Canada that it's ready for cannabis licensing."

Liberty Leaf Holdings Ltd. (LIBFF), closed Thursday's trading session at $0.0486, up 54.7771%, on 15,270 volume with 4 trades. The average volume for the last 3 months is 14,309 and the stock's 52-week low/high is $0.024/$0.1849.

chart

Maricann Group, Inc. (MRRCF)

Weed Newswire, OTC Markets, Barchart, NewCannabisVentures, Stockhouse, Investopedia, Insider Financial, YCharts, The Street, MarketWatch, 4-Traders, Marketwired, Investors Hub, and TradingView reported on Maricann Group, Inc. (MRRCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Maricann Group, Inc. produces and distributes marijuana for medical purposes. The Company offers dried marijuana, cannabis oil, and gums. In addition, it provides accessories. These includes vaporizers, grinders, and other paraphernalia. OTCQB-listed, Maricann Group has its head office in Burlington, Ontario, and Munich, Germany. The Company has production facilities in Langton, Ontario.

On September 24, 2018, Maricann Group announced that it intends to change its name to Wayland Group Corp. In the interim, it expects to start operating via its subsidiaries under the business name “Wayland Group”. In expectation of the proposed name change, the Company also announced that, effective September 25, 2018, its ticker symbol on the Canadian Securities Exchange will be “WAYL”.

The Company is a licensed producer of medical cannabis under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). Maricann Group has federal licenses in Canada to cultivate, extract, formulate, and distribute cannabis.

In Langton, Ontario, Maricann operates a medicinal cannabis cultivation, extraction, and formulation and distribution business under federal license from the Government of Canada, and Dresden, Saxony, Germany. The Company’s new, state-of-the-art, fully dedicated cannabis production facility in Langton is on 100 acres of land. At present, the Company is undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, to support existing and future patient growth.

The Company’s Germany-based Ebersbach facility targets the significant European market with 820,000 sq. ft. of cultivation space and greater than 12,000 patients. Maricann has developed educational programming for patients and healthcare professionals. Through exclusive pharmacy agreements with approximately 20 percent of the nation’s pharmacies, Maricann is working to become a leading provider of cannabis at physical point-of-sale locations that patients trust.

One of Maricann Group’s acquisition’s is NanoLeaf Technologies. NanoLeaf is a biotechnology company. It has licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic, and functional beverage drug delivery formulations. Maricann’s Vesisorb is the first standardized dose cannabinoid soft gel capsule with a nano-dispersed carrier for the drug that is ideal for ingestional bioavailability.

Additionally, Maricann Group acquired Haxxon AG. The acquisition of Haxxon forms an important element of Maricann’s European expansion strategy. Maricann is now positioned to enter the Swiss market via Haxxon’s production of feminized high CBD cannabis plants.

Recently, Maricann (Wayland Group) announced that it will open its first retail location in Zurich, Switzerland in 2019. It will serve the market with high-quality cannabis products, which contain a maximum THC content of 1 percent. The opportunity comes on the heels of the Company’s strategic acquisition of Haxxon AG, granting Maricann (Wayland) the opportunity to take advantage of Haxxon’s production facilities in Regensdorf, Switzerland, and its production of feminized high CBD cannabis plants.

Yesterday, Maricann (Wayland Group) announced that it entered into an agreement to supply Cannamedical Pharma GmbH, a licensed, privately owned importer and distributor of cannabis in Germany to more than 2,200 pharmacies, with a minimum of 9,000 kilograms of EU-GMP certified cannabis flowers over a three year term. The two companies have completed mandatory quality assurance and control audits. They have scheduled the first shipment in December of this year.

Maricann Group, Inc. (MRRCF), closed Thursday's trading session at $0.0274, up 37.00%, on 160,496 volume with 37 trades. The average volume for the last 3 months is 119,124 and the stock's 52-week low/high is $0.0125/$1.25.

chart

The QualityStocks Company Corner

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) was featured today in a report by Motley Fool, examining how it was something of a banner day for Canadian marijuana stocks. What caused all the buzz? Perhaps the most important milestone toward the legalization of marijuana in the U.S. so far was reached yesterday. The U.S. House of Representatives Judiciary Committee voted 24-10 on Wednesday to remove marijuana from the Controlled Substances Act, which would make cannabis legal throughout the U.S.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Thursday's trading session at $2.86, up 16.2602%, on 9,120,727 volume with 25,110 trades. The average volume for the last 3 months is 1,899,629 and the stock's 52-week low/high is $2.00/$8.43999958.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) was featured today in the 420 with CNW by CannabisNewsWire. For centuries, wine merchants have been cognizant that sticking to every step of the winemaking process is crucial in ensuring the quality and value of the end product. So, they have to be cautious from cultivation and harvesting techniques to fermentation, aging, and packaging of the wine. This strict process of winemaking is now being adopted in the production of marijuana.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Thursday's trading session at $1.85, up 23.9448%, on 182,276 volume with 238 trades. The average volume for the last 3 months is 40,381 and the stock's 52-week low/high is $1.08749997/$6.00810003.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was featured today in a publication from HempWireNews, examining how central Indiana has launched its first hemp processing facility for converting hemp into a market-ready product. Last month, Third Wave Farms, a hemp company based in Kentucky, launched its first hemp dying and processing facility inside a 22,000 square-foot building in Kokomo. The building was previously occupied by a company that manufactures parts for the robotics market.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Thursday's trading session at $0.885, up 32.0896%, on 4,518,940 volume with 2,192 trades. The average volume for the last 3 months is 1,168,581 and the stock's 52-week low/high is $0.469300001/$4.38000011.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was highlighted today in a publication from Financialnewsmedia.com, examining how, at the moment, “there are dozens of studies taking place to evaluate the medical safety and efficacy of psychedelics, including psilocybin, and the potential benefits of psychedelics as a treatment for cluster headache, anxiety, addiction to alcohol and other drugs, depression, obsessive-compulsive disorder, as well as neuroimaging experiments furthering the understanding of its effects on the brain,” as reported by Drugpolicy.org. Psychiatrists at Johns Hopkins University and the Multidisciplinary Association for Psychedelic Studies (MAPS) for example are conducting research. Researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. As excitement builds, it’s opening a range of opportunity for companies that have already established launching cannabis products. Also today, the company was highlighted in a publication from CBDWire, examining how UK lifestyle retailer Firebox is looking to cash in on the CBD craze through a completely novel and unique idea; CBD Christmas pudding.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Thursday's trading session at $0.59, up 14.3411%, on 988,818 volume with 680 trades. The average volume for the last 3 months is 542,095 and the stock's 52-week low/high is $0.432000011/$1.7888.

Recent News

chart

Trxade Group Inc. (TRXD)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (TRXD).

Trxade Group, Inc. (OTCQB: TRXD) (“Trxade” or the “Company”), an integrated pharma supply chain and care platform, announced today its wholly-owned subsidiary, Bonum Health, has teamed up with Benzer Pharmacy, a Tampa Bay-based chain of independent retail pharmacies, to launch the “Bonum Health Hub”. Benzer and Bonum Health have agreed for Bonum Health to place its Health Hubs in rural and urban areas where this type of care is hard to come by.

Trxade Group Inc. (TRXD) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade's overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company's pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, "E-Bay/Kayak-like" technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the "consumer side" of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called "Delivmeds" (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade's Managed Services Organization ("TrxadeMSO") enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient's information, thereby ensuring appropriate medication coverage based on the patient's location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade's fair online market platform targets the nation's retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE's programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks ("PAC") to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry.
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE's advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process.

Management Team

Trxade's management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary

Suren Ajjarapu has served as Trxade's chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer

Prashant Patel has served as Trxade's full-time president and COO, and as a director since the company's acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed Thursday's trading session at $1.255, off by 7.037%, on 3,977 volume with 7 trades. The average volume for the last 3 months is 3,161 and the stock's 52-week low/high is $0.230000004/$1.60000002.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs Inc. (NASDAQ: SGLB) announces the availability of a broadcast titled, “Profiting from the Fourth Industrial Revolution.” To hear the NetworkNewsWire Audio version, visit: http://nnw.fm/5Px4W. To read the full editorial, visit: http://nnw.fm/1WhBz.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Thursday's trading session at $0.90, off by 11.7647%, on 218,441 volume with 584 trades. The average volume for the last 3 months is 167,750 and the stock's 52-week low/high is $0.451099991/$2.46000003.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF), an emerging biotechnology company focused on the biosynthetic production of cannabinoids, believes that the cannabis industry presents an exciting opportunity for the well-positioned company. As the market anticipates the legalization of cannabis-derivative products in Canada, and the CBD legal landscape continues to change rapidly in the United States and around the world, cannabinoids are appearing as a key ingredient in a broad range of products, from health and wellness and pet care options to beverages and edibles.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Thursday's trading session at $0.63, off by 5.97%, on 60,100 volume with 15 trades. The average volume for the last 3 months is 84,477 and the stock's 52-week low/high is $0.529999971/$5.25.

Recent News

chart

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings (OTC: MCTC), an innovator in the field of cannabinoid nanoparticles and infusion technologies, today announces it has selected the corporate communications expertise of NetworkNewsWire ("NNW").With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC Holdings plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Thursday's trading session at $0.62, off by 9.6473%, on 13,400 volume with 12 trades. The average volume for the last 3 months is 10,531 and the stock's 52-week low/high is $0.075000002/$3.00.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its development of additional enhancements for its industry-leading DehydraTECH(TM) platform that delivers THC onset of action in less than 10 minutes in human pilot testing. To view the full press release, visit http://cnw.fm/G4mY9.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Thursday's trading session at $0.45, off by 2.7973%, on 157,899 volume with 82 trades. The average volume for the last 3 months is 91,823 and the stock's 52-week low/high is $0.399800002/$1.6875.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX) this morning announced that it will host an investor conference call today, Novemebr 21, 2019, at 4:00 p.m. EST. Per the update, the call will focus on recent company developments. CEO Warren Wang will be on the call to provide insight into CIIX’s fast-growing industrial hemp/CBD business in China, as well as the company’s legacy financial news and information business. To join the call, interested parties should dial (866) 821-0302. To view the full press release, visit http://nnw.fm/ZVQo9. Also today, the company was highlighted in a publication from CBDWire, covering how CEO Warren Wang noted the enormous potential for cosmetics infused with industrial hemp in a recent RedChip Money Report interview. This sentiment was echoed in his letter to shareholders, where he noted that CBD-infused cosmetics will the company and its subsidiary, CBD Biotech, to a Chinese market of 1.4 billion people. CIIX plans to launch industrial hemp-infused wrinkle cream cosmetics to this market in the near future (http://cnw.fm/n4AAE).

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Thursday's trading session at $0.265, off by 0.934579%, on 30,124 volume with 14 trades. The average volume for the last 3 months is 45,375 and the stock's 52-week low/high is $0.165000006/$0.654999971.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

VERB Technology Company, Inc. (NASDAQ: VERB; VERBW) ("VERB" or the "Company"), a leader in business-focused interactive video CRM, marketing, and sales enablement applications, announced that Elepreneurs, a wholly-owned subsidiary of Sharing Services Global Corporation (SHRG) and has adopted VERB’s interactive video-based CRM and sales enablement platform for use by their expansive network of entreprenuers.  Elepreneurs has now launched the VERB application in the US and will soon launch in Canada. In just the first weeks since launch, Elepreneurs’ VERB app has already been widely adopted and garnered hundreds of five-star reviews on the Apple App Store and Google Play Store.  Elepreneurs expects their VERB app will allow them to continue to build on their substantial recent 10X growth.

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed Thursday's trading session at $0.1122, off by 6.50%, on 15,000 volume with 3 trades. The average volume for the last 3 months is 34,732 and the stock's 52-week low/high is $0.090000003/$0.3944.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTCQB: SGSI), a leading single-source provider of next-generation communications network, technology, infrastructure and maintenance solutions, on Wednesday reported financial results for the third quarter ended September 30, 2019. To view the full press release, visit http://nnw.fm/pI0TN.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Thursday's trading session at $0.0346, off by 8.5382%, on 4,844 volume with 2 trades. The average volume for the last 3 months is 187,966 and the stock's 52-week low/high is $0.014999999/$0.419999986.

Recent News

chart

No Borders Inc. (OTC: NBDR)

The QualityStocks Daily Newsletter would like to spotlight No Borders Inc. (NBDR).

Multifaceted holding corporation No Borders Inc. (OTC: NBDR) this morning announced that it has successfully developed and deployed a revolutionary blockchain platform for securely and immutably recording cannabinoid lab test data on its new public blockchain. The company presented this new platform at Blockchain Expo 2019, gaining immediate exposure to a wide audience of industry leaders and professionals. To view the full press release, visit http://cnw.fm/5y4nV.

No Borders Inc. (OTCQB: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

  • No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
  • No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
  • No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
  • No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
  • No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

 

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

No Borders Inc. (NBDR), closed Thursday's trading session at $0.015, off by 6.25%, on 139,090 volume with 4 trades. The average volume for the last 3 months is 77,138 and the stock's 52-week low/high is $0.007699999/$0.048799999.

Recent News

chart

Quest Patent Research Corp. (OTCQB: QPRC)

The QualityStocks Daily Newsletter would like to spotlight Quest Patent Research Corp. (OTCQB: QPRC).

The Power Management/Bus Controller Portfolio, acquired by company Quest Patent Research Corp. (OTCQB: QPRC)from Intellectual Ventures in October 2015 and transferred to wholly owned subsidiary, Semcon IP Inc., consists of four United States patents that cover fundamental technology for adjusting the processor clock and voltage to save power based on the operating characteristics of the processor and one United States patent that relates to coordinating direct bus communications between subsystems in an assigned channel.

Quest Patent Research Corp. (OTCQB: QPRC) is a New York City-based intellectual property (IP) asset management firm operating through majority-owned and controlled operating subsidiaries to deliver financial, strategic and legal resources for IP monetization. Quest currently owns, controls or manages over 115 patents across 11 intellectual property portfolios (https://www.qprc.com/portfolio). The company generates revenues from patent licensing fees of its IP property portfolios and from licensed packaging sales.

Quest creates shareholder value through investment and management interests in intellectual property assets, such as patents, trademarks, copyrights, novel inventions and trade secrets. Through its business, shareholders have the opportunity to participate across a broad portfolio of dynamic assets in the burgeoning intellectual property space.

Objectives

Invention, protection and commercialization of IP require a deep understanding of dynamic technologies, market fundamentals, competitive landscapes and engagement strategies. Often, IP asset owners/stakeholders lack the requisite resources, experience and/or capacity to access the latent value of their IP assets and opportunities. Quest seeks to bridge this gap, partnering with asset owners – such as inventors, businesses, corporations and law firms – to help them fully realize the value of IP assets through:

  • IP Valuation
  • Structured Licensing Programs
  • Patent Prosecution
  • Partial or Full Liquidity
  • Portfolio Evaluation
  • Portfolio Maintenance
  • Legal Advisory
  • Attorney/Investor Referral
  • Patent Acquisition/Liquidation

At Quest, each partnership is treated as its own entity, with its own focused management comprised of Quest employees and seasoned industry associates. Many of technologies are placed in a wholly owned subsidiary of Quest, benefitting from the broader expertise of the company’s leadership.

Management

Quest’s management team delivers a wealth of experience in strategic business management, intellectual property, finance and marketing. The company’s internal resources, in tandem with its external network of financial, legal and managerial professionals, can develop creative solutions to the myriad of challenges involved in monetizing IP. Quest’s structured diligence and deployment procedures mitigate risks, maximize returns and deliver value to IP owners and shareholders alike.

Quest CEO and President Jon Scahill was the founder and managing director of the Urban-Rigney Group, LLC, a private consultancy specializing in new business/new venture development, operations optimization, and strategic analysis. Prior to launching his consultancy business, Mr. Scahill held numerous positions in sales and marketing, technical management, and product development in the consumer products/flexible packaging arena. Mr. Scahill holds a B.S. in chemical engineering from the University of Rochester, an MBA from Rochester’s Simon Graduate School of Business, and a JD from Pace University Law School. He is a registered patent attorney admitted to practice in New York, Florida, the District of Columbia and before the United States Patent and Trademark Office.

Quest Chief Technology Officer Timothy Scahill recently completed a merger and buyout of Managed Services Team LLC, an IT Managed Services provider. Prior to Managed Services Team, he was president of Layer 8 Group Inc., which merged with Structured Technologies Inc. to form Managed Services Team LLC. In his roles he was responsible for business strategy, acquisition, execution, as well as financial management. Mr. Scahill’s entrepreneurial acumen and proven record of successful management with sole discretionary responsibility, demonstrate the scope of his capability and his value to delivering results. He successfully completed his term on the boards of the Upstate New York Technology Council and Pariemus Rochester. Mr. Scahill completed a six-year term as secretary, executive council and a seat on the board of directors for Habitat for Humanity. He has served as president of the Western New York chapter of The Entrepreneurs Organization and continues to serve on the board as accelerator chair. Mr. Scahill is currently performing Cyber Intelligence, Security and Information Assurance work for an undisclosed organization.

Peter LaFauci is president of CFO Solutions, a Rochester, NY-based consulting firm offering knowledge-based financial and accounting solutions for emerging to medium-size companies. Mr. LaFauci is a seasoned executive with over 25 years of proven success in developing, leading and executing strategy in both publicly and privately held companies within the advertising, software development, internet, manufacturing and emerging technologies sectors. Peter possesses strong research and analytical skills as well as interpreting, summarizing and communicating financial and business information to others. Mr. LaFauci is a graduate of Saint Bonaventure University.

Quest Patent Research Corp. (OTCQB: QPRC), closed Thursday's trading session at $0.011, off by 5.9829%, on 145,976 volume with 19 trades. The average volume for the last 3 months is 268,410 and the stock's 52-week low/high is $0.004499999/$0.039999999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.